Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine single-dose versus repeated-dose treatment for treatment-resistant depression
IRCT20210125050137N1Phase 2Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ketamine in treatment-resistant depression (TRD) and major depressive disorder (MDD) (2 arms), sponsored by Kashan University of Medical Sciences. Primary endpoint: Hamilton Depression Rating Scale score. Started Feb 2021; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20210125050137N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210125050137N1.